COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?

J Cardiovasc Med (Hagerstown). 2020 Jul;21(7):465-466. doi: 10.2459/JCM.0000000000000998.
No abstract available

MeSH terms

  • Betacoronavirus / isolation & purification
  • C-Reactive Protein / analysis
  • COVID-19
  • Coronavirus Infections* / blood
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / immunology
  • Cytokine Release Syndrome* / etiology
  • Cytokine Release Syndrome* / immunology
  • Endothelium, Vascular / immunology
  • Endothelium, Vascular / injuries
  • Endothelium, Vascular / physiopathology
  • Humans
  • Interleukin-1 / antagonists & inhibitors
  • Interleukin-1 / immunology*
  • Macrophage Activation / immunology*
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / immunology
  • Myocardial Ischemia* / blood
  • Myocardial Ischemia* / etiology
  • Natriuretic Peptide, Brain / blood
  • Pandemics*
  • Peptide Fragments / blood
  • Pneumonia, Viral* / blood
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / immunology
  • SARS-CoV-2
  • Troponin I / blood

Substances

  • Interleukin-1
  • Peptide Fragments
  • Troponin I
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • C-Reactive Protein